Cencora Inc. ($COR) Stock Forecast: Down 6.3% Today

What is Cencora Inc.?

Cencora (COR) is a pharmaceutical wholesale company that recently finalized a major acquisition and disclosed its Q1 earnings. The stock has demonstrated strong growth in the previous year.

Why is Cencora Inc. going down?

COR stock is down 6.3% on Feb 4, 2026 14:52

• Despite exceeding EPS expectations in Q1, Cencora's stock faced a downward trend, possibly influenced by revenue falling beneath estimates.
• The completion of the OneOncology acquisition and the increased guidance for fiscal 2026 operating income growth were favorable developments for the company.
• The market's negative response to the revenue miss suggests investor focus on top-line performance.
• Concerns about the stock's overvaluation and a slight revenue shortfall in contrast to estimates likely played a role in today's bearish movement.

COR Price Chart

COR Technical Analysis

COR News

Cencora (COR) Q1 Earnings: EPS Surpasses, Revenue Falls Short

Cencora (COR) reported Q1 earnings with a Non-GAAP EPS of $4.08, exceeding expectations, but its revenue of $85.9 billion fell short by $270 million. Despite the revenue miss, Cencora reaffirmed its fiscal 2026 adjusted diluted EPS guidance. The company holds a strong position in the U.S. pharmaceutical wholesale market, though its valuation metrics suggest it may be overvalued.

https://www.gurufocus.com/news/8580067/cencora-cor-q1-earnings-eps-surpasses-revenue-falls-short

Cencora Completes OneOncology Acquisition, Lifts Guidance

Cencora recently finalized its $4.6 billion acquisition of OneOncology, integrating it into U.S. Healthcare Solutions and subsequently raising its fiscal 2026 adjusted operating income growth outlook to 11.5%–13.5%. This follows a strong Q1 2026 performance with revenue up 5.5% year-over-year to $85.9 billion and adjusted diluted EPS increasing by 9.4% to $4.08. Spark, TipRanks' AI Analyst, rates Cencora (COR) as Neutral, citing solid financials and positive earnings outlook, balanced by high leverage and valuation.

https://www.tipranks.com/news/company-announcements/cencora-completes-oneoncology-acquisition-lifts-guidance

Cencora Inc earnings beat by $0.04, revenue fell short of estimates

Cencora Inc (NYSE: COR) reported first-quarter EPS of $4.08, surpassing analyst estimates by $0.04, although its revenue of $85.9 billion fell short of the consensus estimate of $86.02 billion. The company provided a FY 2026 EPS guidance of $17.45-$17.75, aligning with analyst expectations. Cencora's stock has seen significant growth, up 42.83% in the last 12 months, and maintains a "great performance" financial health score according to InvestingPro.

https://ng.investing.com/news/earnings/cencora-inc-earnings-beat-by-004-revenue-fell-short-of-estimates-2322550

Earnings Flash (COR) Cencora, Inc. Reports Q1 Revenue $85.93B, vs. FactSet Est of $86.06B

Cencora, Inc. (COR) reported its first-quarter revenue of $85.93 billion, falling slightly short of FactSet's estimate of $86.06 billion. This financial update provides key performance indicators for the company's recent quarter. The article also mentions that Cencora posted Q1 Adjusted EPS of $4.08 per share, which exceeded FactSet's estimate of $4.05.

https://www.marketscreener.com/news/earnings-flash-cor-cencora-inc-reports-q1-revenue-85-93b-vs-factset-est-of-86-06b-ce7e5adadb80f127

Cencora Inc earnings beat by $0.04, revenue fell short of estimates

Cencora Inc (NYSE: COR) reported first-quarter earnings per share (EPS) of $4.08, surpassing analyst estimates by $0.04, although its revenue of $85.9 billion fell slightly short of the consensus estimate of $86.02 billion. The company provided fiscal year 2026 EPS guidance of $17.45-$17.75, aligning with analyst expectations. Cencora's stock has shown strong performance, increasing by 42.83% over the last 12 months, and its financial health is rated as "great performance" by InvestingPro.

https://za.investing.com/news/earnings/cencora-inc-earnings-beat-by-004-revenue-fell-short-of-estimates-4095070

Trending Today

StoneCo Ltd. ($STNE) Stock Forecast: Down 5.4% Today

Enphase Energy Inc. ($ENPH) Stock Forecast: Up 38.0% Today

Opendoor Technologies Inc. ($OPEN) Stock Forecast: Down 5.6% Today

Riot Platforms, Inc. ($RIOT) Stock Forecast: Down 11.8% Today

DaVita Inc. ($DVA) Stock Forecast: Up 6.6% Today

Lemonda Inc. ($LMND) Stock Forecast: Down 10.2% Today

Fortune Brands Innovations Inc. ($FBIN) Stock Forecast: Up 5.5% Today

Voya Financial Inc. ($VOYA) Stock Forecast: Down 7.6% Today

Wynn Resorts Limited ($WYNN) Stock Forecast: Up 5.1% Today

Deutsche Bank AG ($DB) Stock Forecast: Down 5.1% Today

Cencora Inc. Price History

23.08.2025 - COR Stock was up 5.1%

• The strong bullish movement in Cencora (NYSE: COR) today may be linked to its impressive long-term outperformance of the market, boasting an average annual return of 20.51% over the past decade.
• Investors seem to be drawn to COR because of its consistent growth and its ability to produce returns that surpass the market average significantly.
• The coverage of COR's exceptional performance in recent times could have further piqued investor interest, leading to an increase in the stock price.

06.00.2026 - COR Stock was up 5.1%

• The bullish movement in Cencora's stock today can be attributed to the strong fiscal second-quarter results from a key player in the pharmaceutical distribution industry.
• Impressive earnings momentum from specialty and automation services in the sector has likely boosted investor confidence industry-wide, including companies like Cencora.
• Concerns raised about Cencora's valuation and lowered price target have been overshadowed by the overall positive outlook for the company, particularly with its recent acquisition and growth targets.
• The increasing interest from institutional investors and hedge funds in Cencora, as noted in the ownership structure, indicates growing confidence in the company's future prospects, contributing to the bullish trend observed today.

08.04.2025 - COR Stock was down 4.2%

• Despite surpassing Q2 earnings and revenue estimates, COR witnessed a bearish movement in the market.
• Concerns about revenue sustainability and competition in the pharmaceutical sector may have contributed to the market's negative reaction.
• Investor caution regarding the company's growth sustainability could result in profit-taking and a bearish stock price trend.
• Broader economic factors and sector-specific challenges in the pharmaceutical industry might also influence the market movement.

08.04.2025 - COR Stock was down 5.2%

• Despite surpassing Q2 earnings and revenue expectations, COR observed a decline in its stock price today.
• The high demand for weight loss drugs and specialty products might not have sustained the stock's elevated value, resulting in profit-taking by traders.
• The market's response could be due to concerns regarding future growth prospects or uncertainties about the company's trajectory.
• Investors may have anticipated stronger results or guidance from COR, triggering a stock sell-off despite its recent accomplishments in the healthcare solutions industry.

05.00.2026 - COR Stock was down 0.6%

• A notable adjustment was made to COR's price target by B of A Securities, lowering it from $380.00 to $360.00. This change, amidst other analysts raising their targets, may have contributed to the bearish movement.
• Institutional confidence in COR was highlighted when Gateway Investment Advisers LLC significantly increased its stake in the company by 1,135.4% to $37.23 million. However, recent insider selling activities may have raised concerns among investors.
• Comments on COR's strong fundamentals, resilient earnings, and strategic focus on specialty distribution and biosimilars have surfaced, suggesting a positive outlook. This implies that the bearish movement could be a temporary correction rather than an indicator of the company's long-term potential.
• The market movements observed today regarding COR could be explained by short-term price adjustments resulting from conflicting analyst opinions and profit-taking behaviors following a period of consistent value appreciation.

15.08.2025 - COR Stock was down 1.9%

• The factors behind the bearish movement in COR include:
• Investors taking profits following a recent uptrend.
• Worries about decreased demand for cloud computing services.
• Negative impact of overall market sentiment on tech stocks.
• Absence of specific positive news or catalysts to drive buying activity for COR.

04.01.2026 - COR Stock was down 6.3%

• Despite exceeding EPS expectations in Q1, Cencora's stock faced a downward trend, possibly influenced by revenue falling beneath estimates.
• The completion of the OneOncology acquisition and the increased guidance for fiscal 2026 operating income growth were favorable developments for the company.
• The market's negative response to the revenue miss suggests investor focus on top-line performance.
• Concerns about the stock's overvaluation and a slight revenue shortfall in contrast to estimates likely played a role in today's bearish movement.

05.10.2025 - COR Stock was down 0.1%

• Despite Cencora (COR) surpassing earnings and revenue estimates for Q4, the stock exhibited bearish movement.
• Investors may have had higher expectations or anticipated growth projections beyond the reported numbers, resulting in a sell-off.
• Market sentiment could have been swayed by external factors such as macroeconomic uncertainties or industry shifts, rather than the company's financial achievements.
• Some investors might have opted to take profits after the positive news, leading to a temporary decline in the stock price.

07.04.2025 - COR Stock was up 5.7%

• COR outperformed Q2 earnings and revenue expectations, signaling robust financial results.
• The U.S. Healthcare Solutions segment's favorable outlook is anticipated to be a key driver of COR's success.
• Analysts hold a positive view on COR's crucial metrics for the quarter, indicating a favorable path for the company.
• Investors reacted favorably to the strong performance and growth potential of COR, leading to the uptrend in the stock price.

16.11.2025 - COR Stock was down 2.4%

• Factors contributing to the bearish movement in Cencora's stock (COR) today include:
• Concerns over the significant financial commitment of $5 billion for the OneOncology acquisition, impacting immediate financials.
• Investor caution regarding the initial EPS neutrality and timeline for positive contribution from the deal by mid-fiscal year 2027, despite positive analyst sentiment and raised price targets post-acquisition.
• Influence of recent market fluctuations and economic data on broader market sentiment, potentially affecting COR stock movement.
• Investor hesitancy as they wait to see the ultimate impact of OneOncology acquisition on Cencora's market position and financial performance, resulting in a temporary decline in stock price.

06.07.2025 - COR Stock was down 6.4%

• The bearish movement in COR stock today may be linked to the market's reaction to the company's Q3 earnings, despite exceeding earnings and revenue expectations. Here's a breakdown of the situation:
• The market could have anticipated more robust results given COR's consistent outperformance, leading to a sell-off.
• Worries about international challenges impacting Q3 figures might have unsettled investors, overshadowing the positive earnings beats.
• Investors expecting a significant earnings beat based on Wall Street projections might have felt let down, resulting in a decline in the stock's value.
• While hopes were high for COR's earnings growth, the market's response today indicates that even surpassing estimates does not always guarantee a positive reaction from investors.

31.06.2025 - COR Stock was down 2.4%

• The decline in COR's stock today could be due to profit-taking by investors who were possibly anticipating a positive earnings outcome.
• Comparisons with McKesson (MCK) in the medical sector may have impacted investor sentiment, resulting in a sell-off of COR as it might have shown lower performance compared to its sector so far this year.
• Investors might be reassessing their holdings in COR based on its performance relative to McKesson, potentially influencing the downward trend in the stock.